Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$0.6406
0.0712.23%
At close: -
$0.6250
-0.02-2.44%
After Hours: May 16, 7:58 PM EDT
Comments
Loading...
Rani Therapeutics Hldgs Analyst Ratings and Price Targets | NASDAQ:RANI | Benzinga
Rani Therapeutics Holdings Inc has a consensus price target of $11 based on the ratings of 10 analysts. The high is $17 issued by B of A Securities on August 21, 2023. The low is $4 issued by Oppenheimer on May 16, 2025. The 3 most-recent analyst ratings were released by Oppenheimer, HC Wainwright & Co., and Canaccord Genuity on May 16, 2025, April 3, 2025, and February 26, 2025, respectively. With an average price target of $7.33 between Oppenheimer, HC Wainwright & Co., and Canaccord Genuity, there's an implied 1073.33% upside for Rani Therapeutics Holdings Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Oppenheimer
HC Wainwright & Co.
Canaccord Genuity
HC Wainwright & Co.
Maxim Group
1calculated from analyst ratings
Analyst Ratings for Rani Therapeutics Hldgs
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 05/16/2025 | Buy Now | 540% | Oppenheimer | Andreas Argyrides70% | $14 → $4 | Maintains | Outperform | Get Alert |
| 04/03/2025 | Buy Now | 1340% | HC Wainwright & Co. | Mitchell Kapoor42% | $9 → $9 | Reiterates | Buy → Buy | Get Alert |
| 02/26/2025 | Buy Now | 1340% | Canaccord Genuity | Edward Nash65% | $9 → $9 | Maintains | Buy | Get Alert |
| 02/07/2025 | Buy Now | 1340% | HC Wainwright & Co. | Raghuram Selvaraju42% | $9 → $9 | Reiterates | Buy → Buy | Get Alert |
| 11/19/2024 | Buy Now | 1340% | HC Wainwright & Co. | Mitchell Kapoor42% | $9 → $9 | Reiterates | Buy → Buy | Get Alert |
| 10/18/2024 | Buy Now | 1340% | HC Wainwright & Co. | Mitchell Kapoor42% | $9 → $9 | Reiterates | Buy → Buy | Get Alert |
| 08/16/2024 | Buy Now | 1340% | HC Wainwright & Co. | Mitchell Kapoor42% | $13 → $9 | Maintains | Buy | Get Alert |
| 08/02/2024 | Buy Now | 2620% | Oppenheimer | Andreas Argyrides70% | → $17 | Initiates | → Outperform | Get Alert |
| 06/25/2024 | Buy Now | 1980% | HC Wainwright & Co. | Mitchell Kapoor42% | $13 → $13 | Reiterates | Buy → Buy | Get Alert |
| 06/14/2024 | Buy Now | 2300% | Maxim Group | — | → $15 | Initiates | → Buy | Get Alert |
| 06/13/2024 | Buy Now | 1500% | Rodman & Renshaw | Brandon Folkes38% | → $10 | Initiates | → Buy | Get Alert |
| 05/09/2024 | Buy Now | 2140% | BTIG | Robert Hazlett33% | $7 → $14 | Maintains | Buy | Get Alert |
| 05/07/2024 | Buy Now | 1980% | HC Wainwright & Co. | Mitchell Kapoor42% | $12 → $13 | Maintains | Buy | Get Alert |
| 03/27/2024 | Buy Now | 1340% | Canaccord Genuity | Edward Nash65% | $21 → $9 | Maintains | Buy | Get Alert |
| 03/25/2024 | Buy Now | 1820% | HC Wainwright & Co. | Mitchell Kapoor42% | $16 → $12 | Maintains | Buy | Get Alert |
| 02/06/2024 | Buy Now | 1180% | Wedbush | Andreas Argyrides70% | $8 → $8 | Reiterates | Outperform → Outperform | Get Alert |
| 11/09/2023 | Buy Now | 2460% | HC Wainwright & Co. | Mitchell Kapoor42% | $20 → $16 | Maintains | Buy | Get Alert |
| 09/20/2023 | Buy Now | 3100% | HC Wainwright & Co. | Mitchell Kapoor42% | → $20 | Reiterates | Buy → Buy | Get Alert |
| 09/08/2023 | Buy Now | 3100% | HC Wainwright & Co. | Mitchell Kapoor42% | → $20 | Reiterates | Buy → Buy | Get Alert |
| 08/21/2023 | Buy Now | 2620% | B of A Securities | Geoff Meacham60% | $19 → $17 | Maintains | Buy | Get Alert |
| 08/17/2023 | Buy Now | 3100% | Wedbush | Andreas Argyrides70% | → $20 | Reiterates | Outperform → Outperform | Get Alert |
| 08/14/2023 | Buy Now | 3100% | HC Wainwright & Co. | Mitchell Kapoor42% | $22 → $20 | Maintains | Buy | Get Alert |
| 06/06/2023 | Buy Now | 3420% | HC Wainwright & Co. | Mitchell Kapoor42% | → $22 | Reiterates | Buy → Buy | Get Alert |
| 05/11/2023 | Buy Now | 3420% | HC Wainwright & Co. | Mitchell Kapoor42% | → $22 | Reiterates | Buy → Buy | Get Alert |
| 03/23/2023 | Buy Now | 3420% | HC Wainwright & Co. | Mitchell Kapoor42% | → $22 | Reiterates | → Buy | Get Alert |
| 10/11/2022 | Buy Now | 2300% | UBS | Ashwani Verma46% | → $15 | Initiates | → Buy | Get Alert |
| 07/27/2022 | Buy Now | 3420% | HC Wainwright & Co. | Mitchell Kapoor42% | → $22 | Initiates | → Buy | Get Alert |
| 06/13/2022 | Buy Now | 4380% | Wedbush | Andreas Argyrides70% | → $28 | Initiates | → Outperform | Get Alert |
FAQ
What is the target price for Rani Therapeutics Hldgs (RANI) stock?
The latest price target for Rani Therapeutics Hldgs (NASDAQ:RANI) was reported by Oppenheimer on May 16, 2025. The analyst firm set a price target for $4.00 expecting RANI to rise to within 12 months (a possible 540.00% upside). 11 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Rani Therapeutics Hldgs (RANI)?
The latest analyst rating for Rani Therapeutics Hldgs (NASDAQ:RANI) was provided by Oppenheimer, and Rani Therapeutics Hldgs maintained their outperform rating.
When was the last upgrade for Rani Therapeutics Hldgs (RANI)?
There is no last upgrade for Rani Therapeutics Hldgs
When was the last downgrade for Rani Therapeutics Hldgs (RANI)?
There is no last downgrade for Rani Therapeutics Hldgs.
When is the next analyst rating going to be posted or updated for Rani Therapeutics Hldgs (RANI)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Rani Therapeutics Hldgs, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Rani Therapeutics Hldgs was filed on May 16, 2025 so you should expect the next rating to be made available sometime around May 16, 2026.
Is the Analyst Rating Rani Therapeutics Hldgs (RANI) correct?
While ratings are subjective and will change, the latest Rani Therapeutics Hldgs (RANI) rating was a maintained with a price target of $14.00 to $4.00. The current price Rani Therapeutics Hldgs (RANI) is trading at is $0.63, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
